ETCTN Trials by Disease/ Treatment Area: Sarcoma

- **Sarcoma**
  - **Alveolar soft part sarcoma**
    - 10005: A Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Alveolar Soft Part Sarcoma
  - **Unresectable or metastatic epithelioid hemangioendothelioma**
    - 10015: A Non-Randomized, Open-Label, Phase 2 Study of Trametinib in Patients with Unresectable or Metastatic Epithelioid Hemangioendothelioma
  - **Potentially resectable: liposarcoma, leiomyosarcoma, or undifferentiated pleomorphic sarcoma (UPS)/ malignant fibrous histiosarcoma (MFH)**
  - **Chondrosarcoma**
    - 10056: A Phase 2 Study of Talimogene Laherparepvec (T-VEC) and Radiation in Localized Soft Tissue Sarcoma
    - 10330: A Phase II Study of Belinostat and SGI-110 (Guadecitabine) for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma
    - 10398: A Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Chondrosarcoma and Clear Cell Sarcoma
  - **Kaposi’s sarcoma**
    - ▼* 10387: Pilot Trial of Nivolumab Plus Cabozantinib for Advanced Solid Tumors in Patients with HIV Infection (Dose-Escalation: advanced solid tumors in patients with HIV infection; Expansion cohort: Kaposi’s sarcoma)
    - ▼* 10411: Phase II Study of Rogaratinib in the Treatment of Patients with Sarcoma Harboring Alterations in FGFR 1-4
  - **Histology-confirmed EWSR1 translocation-positive clear cell sarcoma or conventional or dedifferentiated chondrosarcoma**

---

NOTE: * No ClinicalTrials.gov webpage is available at this time (typically for approved LOIs or protocols in review); ▼ Limited trial; not open ETCTN-wide; Version Date: July 13, 2020